A retrospective study to investigate the efficacy of a fluocinolone acetonide implant (Retisert®) combined with an Ahmed™ glaucoma valve compared to an Ahmed valve alone in patients with uveitis

Trial Profile

A retrospective study to investigate the efficacy of a fluocinolone acetonide implant (Retisert®) combined with an Ahmed™ glaucoma valve compared to an Ahmed valve alone in patients with uveitis

Completed
Phase of Trial: Phase IV

Latest Information Update: 05 Jan 2016

At a glance

  • Drugs Fluocinolone acetonide (Primary)
  • Indications Open-angle glaucoma; Uveitis
  • Focus Therapeutic Use
  • Most Recent Events

    • 05 Jan 2016 New trial record
    • 01 Dec 2015 Primary endpoint (Surgical success), has been met according to results published in the Ophthalmology and Therapy.
    • 01 Dec 2015 Results published in the Ophthalmology and Therapy
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top